CTONG1104: adjuvant gefitinib versus chemotherapy for resected N1-N2 NSCLC with EGFR mutation—final overall survival analysis of the randomized phase III trial …

YL Wu, W Zhong, Q Wang, W Mao, ST Xu, L Wu… - 2020 - ascopubs.org
9005 Background: ADJUVANT-CTONG1104, a randomized phase 3 trial showed adjuvant
gefitinib treatment significantly improved disease-free survival (DFS) vs standard doublet …
被引用次数：69 相关文章

CTONG1104: Adjuvant gefitinib versus chemotherapy for resected N1-N2 NSCLC with EGFR mutation—Final overall survival analysis of the randomized phase III trial …

YL Wu, W Zhong, Q Wang, W Mao, ST Xu… - Journal of Clinical …, 2020 - cir.nii.ac.jp
抄録< jats: p> 9005</jats: p>< jats: p> Background: ADJUVANT-CTONG1104, a randomized
phase 3 trial showed adjuvant gefitinib treatment significantly improved disease-free survival …